Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 5.4% Today

What is Amylyx Pharmaceuticals?

Asset Amylyx Pharmaceuticals (Nasdaq: AMLX) is a biopharmaceutical company focused on developing therapies for diseases with high unmet medical needs. AMLX had a strong bullish movement today in the market.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 5.4% on Feb 27, 2026 17:45

• Amylyx Pharmaceuticals' stock (AMLX) experienced a bullish movement due to its participation in upcoming investor conferences and potential positive outcomes from its pipeline therapies.
• The Chief Legal Officer, Gina Mazzariello, sold shares, but this did not impact investors significantly, with several analysts increasing their valuation estimates for AMLX, showing faith in the company's pipeline.
• The forthcoming announcement of financial results on March 3, 2026, added to the positive outlook on AMLX, with investors awaiting insights into the company's performance and future prospects.
• Although concerns were voiced by TipRanks' AI Analyst, Spark, about financial performance and technicals, overall market sentiment towards Amylyx Pharmaceuticals remained positive, leading to the uptrend in the stock price.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals announced its management will participate in two upcoming March investor conferences: the Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference. Live webcasts of both presentations will be available on the company’s investor relations website, with replays accessible for 90 days following the events. Amylyx is focused on developing therapies for diseases with high unmet medical needs.

https://www.joplinglobe.com/region/national_business/amylyx-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences/article_bf0d61f3-990e-5aef-9781-0f50cf874684.html

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals (Nasdaq: AMLX) announced that its management will participate in two upcoming in-person investor conferences in March 2026. These include the TD Cowen 46th Annual Health Care Conference on March 3rd and the Leerink Global Healthcare Conference on March 10th. Live webcasts and replays of these presentations will be available on the company's investor relations website.

https://www.businesswire.com/news/home/20260226194969/en/Amylyx-Pharmaceuticals-to-Participate-in-Upcoming-March-Investor-Conferences

Top Amylyx Pharma Insider Makes Notable Move With Fresh Stock Sale

Amylyx Pharmaceuticals Chief Legal Officer, Gina Mazzariello, recently sold 3,419 shares worth $48,344. This insider transaction comes as multiple analysts, including BofA, Mizuho, and H.C. Wainwright, have raised their valuation outlooks for AMLX, primarily due to reassessments of its pipeline, particularly avexitide and the LUCIDITY trial design. Despite positive clinical program re-evaluations, TipRanks’ AI Analyst, Spark, rates AMLX as Neutral, citing weak financial performance and near-term overbought technicals.

https://www.tipranks.com/news/insider-trading/top-amylyx-pharma-insider-makes-notable-move-with-fresh-stock-sale-insider-trading-news?mod=mw_quote_news

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Amylyx Pharmaceuticals (Nasdaq: AMLX) announced it will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. The company's senior management will host a conference call and audio webcast at 8:00 a.m. ET to discuss these results and provide other company updates. Interested parties can access the call via phone or a live audio webcast on Amylyx's investor relations website, with a replay available for 90 days.

https://www.biospace.com/press-releases/amylyx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-3-2026

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Amylyx Pharmaceuticals will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. The company's senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss these results and provide other company updates. A live audio webcast will be available on the Investors section of the company's website, with an archive available for 90 days.

https://www.bdtonline.com/news/nation_world/amylyx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-3/article_54a4293a-cd7a-5952-bfab-69b3e616b40c.html

Trending Today

Solana ($SOL) Crypto Forecast: Up 6.6% Today

Ethereum ($ETH) Crypto Forecast: Up 5.3% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.9% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 5.2% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.3% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Up 5.2% Today

TE Connectivity Ltd. New Switzerland Registered Shares ($TEL) Stock Forecast: Down 3.2% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Up 4.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 6.0% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 5.0% Today

Amylyx Pharmaceuticals Price History

26.01.2026 - AMLX Stock was up 5.4%

• The positive market performance of Amylyx Pharmaceuticals could be attributed to the optimistic outlook and anticipation surrounding the forthcoming financial results disclosure.
• FDA's contentious approval of the ALS drug, Relyvrio, and the challenges faced by Biogen and Ionis Pharmaceuticals in halting their ALS drug, BIIB105, may have created a conducive environment for companies like Amylyx Pharmaceuticals in the ALS treatment sector.
• Investors may be hopeful about Amylyx's prospects in the ALS market, given the pressing need for effective treatments and recent industry advancements.
• The favorable response from the market to Amylyx Pharmaceuticals could also be influenced by the company's strategic positioning and growth prospects in the field of neurodegenerative disease treatment.

24.01.2026 - AMLX Stock was up 6.0%

• AMLX experienced a strong bullish movement likely due to the FDA approval of Relyvrio, a new ALS drug, despite controversies surrounding its preliminary trial data. This approval signifies potential growth opportunities for AMLX in the ALS treatment market.
• The decision by Biogen and Ionis Pharmaceuticals to shelve their ALS drug development after a study failure could have further boosted investor confidence in AMLX as it positions itself favorably in the competitive landscape.
• The setbacks in ALS drug development faced by other companies highlight the challenges in the industry, making AMLX a potentially attractive investment option for traders seeking growth in the pharmaceutical sector.

20.00.2026 - AMLX Stock was up 5.8%

• Insider selling of shares worth US$2.0 million despite a 15% gain this week may suggest potential concerns about future weakness in the stock.
• The fact that insiders are selling shares at or below the current trading price could indicate a lack of confidence in the stock's valuation.
• Despite some insider buying activity, the overall trend of selling outweighing buying implies a bearish sentiment among insiders regarding the stock's future performance.
• This insider activity might have contributed to the bullish movement in AMLYX today, as investors could be interpreting it as a signal of potential positive developments or upcoming news that could drive the stock price higher.

20.00.2026 - AMLX Stock was up 15.4%

• The selection of AMX0318 as a new development candidate for rare endocrine diseases is believed to have spurred a positive reaction and optimism from investors regarding the company's future pipeline.
• Despite some insider selling amidst the recent stock price growth, the market's response to the new development candidate appears to have overshadowed these worries, resulting in the stock's upward movement.
• Investors may view the appointment of AMX0318 as a signal of Amylyx Pharmaceuticals' dedication to innovation and expansion, fueling interest in the stock.
• The company's strategic emphasis on tackling unmet medical requirements in rare diseases could be interpreted as a favorable long-term investment opportunity, contributing to the positive market activity of AMLX.

21.00.2026 - AMLX Stock was up 10.8%

• AMLX stock witnessed a strong uptrend, rising by 8.85% on January 20th and peaking at $15.57 during the trading day.
• The upswing in the stock price is linked to the selection of AMX0318 as a potential treatment for rare endocrine disorders, signaling the company's dedication to broadening its product portfolio.
• Despite notable selling of shares by company co-CEOs for managing option expenses and taxes, positive market sentiment persists due to Mizuho's endorsement and confidence in AMLX's GLP-1 initiative and product pipeline.
• Analysts foresee a target price averaging $20.22, representing a potential 29.92% increase, endorsed by the general "Buy" stance from brokerage entities, reinforcing a positive outlook for AMLX stock.

04.01.2026 - AMLX Stock was down 6.2%

• The Co-Chief Executive Officer selling a significant amount of AMLX shares to cover option costs and tax obligations likely raised concerns among investors, indicating lack of confidence in the stock.
• The ongoing investigations into alleged breaches of fiduciary duties by Amylyx Pharmaceuticals officers and directors could have contributed to the negative sentiment surrounding the stock.
• Shareholders being encouraged to discuss their rights and potential legal actions against the company's management might have added to the uncertainty and selling pressure on AMLX shares.
• The combination of executive selling, fiduciary duty investigations, and shareholder rights discussions could have created a perfect storm of negative news leading to the bearish movement in AMLX stock today.

11.01.2026 - AMLX Stock was down 5.2%

• Positive forecasts and a raised price target did not prevent a bearish movement in the stock of Amylyx Pharmaceuticals (AMLX).
• Insider transactions, with a director buying shares and the CEO selling some, may have contributed to investor uncertainty.
• Despite strong financial health and significant cash reserves, Amylyx Pharmaceuticals is not yet profitable.
• The market's cautious response to the company's path to avexitide approval, despite a "structurally de-risked" trial design, led to the downward trend in the stock price.

28.00.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX today could be attributed to insider selling activities, with 157,783 shares sold in the past 90 days, potentially signaling lack of confidence from within the company.
• Despite positive analyst sentiment and a high price target, the recent insider selling totaling over $2.12 million in the last quarter might have spooked investors, leading to the bearish movement.
• The news of Gubra securing milestones and royalties from Amylyx Pharmaceuticals could have also impacted the stock negatively, as it highlights potential competition and collaboration dynamics in the industry.
• The stock hitting a 52-week high recently might have prompted profit-taking by investors, contributing to the bearish movement as traders lock in gains.

16.00.2026 - AMLX Stock was up 6.5%

• AMLX stock surged today following the announcement of AMX0318 as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. This positive news regarding the expansion of their pipeline beyond neurology and into rare diseases has likely fueled investor optimism.
• The selection of AMX0318, a long-acting GLP-1 receptor antagonist with promising preclinical properties, signifies a strategic move by Amylyx Pharmaceuticals to diversify its portfolio and address unmet medical needs in different therapeutic areas.
• Investors seem to be responding favorably to the company's proactive approach in advancing AMX0318 towards IND-enabling studies and the upcoming topline data release from the Phase 3 LUCIDITY trial for avexitide, indicating confidence in the company's future growth prospects.
• Amylyx Pharmaceuticals' strategic decision to enter the rare diseases market and broaden its focus beyond neurology has likely reshaped its investment narrative, attracting attention from investors looking for opportunities in the biopharmaceutical sector.

23.00.2026 - AMLX Stock was down 6.9%

• Amylyx Pharmaceuticals (AMLX) observed a decrease in stock value despite achieving a new 52-week high and notable growth in the past year.
• The announcement of Gubra securing milestones and royalty upside for AMX0318, a GLP-1 receptor antagonist, raised concerns about potential competition or market saturation in the pharmaceutical sector.
• Insider selling by the CEO and other executives, surpassing $2 million, may have indicated a lack of confidence in the company's future, leading to stock price decline.
• Despite advancements in its drug pipeline and financial position, concerns about market saturation, coupled with insider selling, likely prompted profit-taking and a bearish sentiment among investors.

27.01.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals' stock (AMLX) experienced a bullish movement due to its participation in upcoming investor conferences and potential positive outcomes from its pipeline therapies.
• The Chief Legal Officer, Gina Mazzariello, sold shares, but this did not impact investors significantly, with several analysts increasing their valuation estimates for AMLX, showing faith in the company's pipeline.
• The forthcoming announcement of financial results on March 3, 2026, added to the positive outlook on AMLX, with investors awaiting insights into the company's performance and future prospects.
• Although concerns were voiced by TipRanks' AI Analyst, Spark, about financial performance and technicals, overall market sentiment towards Amylyx Pharmaceuticals remained positive, leading to the uptrend in the stock price.

30.00.2026 - AMLX Stock was down 5.6%

• There is an ongoing investigation regarding potential breaches of fiduciary duties by certain officers and directors of Amylyx Pharmaceuticals, which may have prompted investor concerns and a subsequent sell-off.
• While HC Wainwright offered a positive earnings estimate for FY2030, insider selling of shares and an uptick in institutional holdings could have spurred uncertainty and contributed to the downward trend.
• Analysts have given an average recommendation of "Moderate Buy" for the stock, and with the stock trading above its moving averages, mixed sentiments in the market may have led to a lack of clear direction and the ensuing decline in stock value.